We are working on the following new projects:

• We were awarded with a contract for medical writing activities with pelubiprofen.
• We are negotiating contracts for full-service support in bioequivalence trials with Rivaroxaban 10 mg and 20 mg.

We are happy to reach the following milestones in our projects:

• The first subject was screened in India in the international phase III clinical trial of the original drug for the patients with chronic myeloid leukemia.
• The clinical part was already finished in the Sildenafil, Rivaroxaban 10 mg, Rivaroxaban 20 mg and Gabapentin trials.
• SIVs were performed in late of August 2022 in the Apixaban, Hymecromone, Dapagliflozin and Rosuvastatin trials, for one of them all subjects were randomized in due time.